Guggenheim upgraded shares of Core Laboratories (NYSE:CLB) from a neutral rating to a buy rating in a research note released on Friday morning, MarketBeat Ratings reports. The firm currently has $120.00 price target on the oil and gas company’s stock.

A number of other analysts have also issued reports on CLB. JPMorgan Chase & Co. cut their price target on shares of Core Laboratories from $121.00 to $118.00 and set an overweight rating on the stock in a research note on Friday, July 27th. Piper Jaffray Companies restated a hold rating and set a $96.00 target price on shares of Core Laboratories in a research note on Friday, July 27th. Citigroup upgraded shares of Core Laboratories from a sell rating to a neutral rating and set a $117.00 target price on the stock in a research note on Monday, August 13th. Edward Jones started coverage on shares of Core Laboratories in a research note on Tuesday, September 4th. They set a buy rating on the stock. Finally, ValuEngine upgraded shares of Core Laboratories from a hold rating to a buy rating in a research note on Tuesday, September 4th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and eight have given a buy rating to the stock. The stock has an average rating of Hold and an average target price of $112.08.

Shares of NYSE:CLB opened at $86.48 on Friday. The company has a debt-to-equity ratio of 1.83, a quick ratio of 1.85 and a current ratio of 2.31. The stock has a market cap of $3.82 billion, a price-to-earnings ratio of 43.24, a price-to-earnings-growth ratio of 2.54 and a beta of 1.64. Core Laboratories has a 1 year low of $80.22 and a 1 year high of $130.34.

Core Laboratories (NYSE:CLB) last issued its quarterly earnings results on Wednesday, October 24th. The oil and gas company reported $0.64 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.63 by $0.01. The company had revenue of $182.15 million for the quarter, compared to analyst estimates of $178.11 million. Core Laboratories had a net margin of 13.21% and a return on equity of 68.00%. The business’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.46 earnings per share. Analysts anticipate that Core Laboratories will post 2.31 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 20th. Shareholders of record on Friday, October 19th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Thursday, October 18th. This represents a $2.20 annualized dividend and a yield of 2.54%. Core Laboratories’s dividend payout ratio is currently 110.00%.

A number of institutional investors have recently made changes to their positions in the business. Crossmark Global Holdings Inc. increased its stake in Core Laboratories by 11.1% in the second quarter. Crossmark Global Holdings Inc. now owns 4,910 shares of the oil and gas company’s stock valued at $620,000 after purchasing an additional 490 shares during the last quarter. Oregon Public Employees Retirement Fund increased its stake in Core Laboratories by 3.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 17,046 shares of the oil and gas company’s stock valued at $2,151,000 after purchasing an additional 496 shares during the last quarter. Conestoga Capital Advisors LLC increased its stake in Core Laboratories by 4.5% in the second quarter. Conestoga Capital Advisors LLC now owns 13,387 shares of the oil and gas company’s stock valued at $1,690,000 after purchasing an additional 575 shares during the last quarter. American International Group Inc. increased its stake in Core Laboratories by 0.7% in the second quarter. American International Group Inc. now owns 87,948 shares of the oil and gas company’s stock valued at $11,100,000 after purchasing an additional 628 shares during the last quarter. Finally, Signaturefd LLC increased its stake in Core Laboratories by 403.7% in the second quarter. Signaturefd LLC now owns 811 shares of the oil and gas company’s stock valued at $102,000 after purchasing an additional 650 shares during the last quarter.

Core Laboratories Company Profile

Core Laboratories N.V. provides reservoir description, and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates in two segments, Reservoir Description and Production Enhancement segments. The Reservoir Description segment comprises the characterization of petroleum reservoir rock, fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs.

See Also: Determine Your Level of Risk Tolerance

Analyst Recommendations for Core Laboratories (NYSE:CLB)

Receive News & Ratings for Core Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.